Haber M; Kavallaris M, 2000, 'Multidrug Resistance Genes in Neuroblastoma', in Neuroblastoma, edn. Original, Elsevier Science BV, Amsterdam, pp. 207 - 215

Tsoli M; Wadham C; Pinese M; Failes T; Joshi S; Mould E; Yin JX; Gayevskiy V; Kumar A; Kaplan W, 2018, 'Integration of genomics, high throughput drug screening, and personalized xenograft models as a novel precision medicine paradigm for high risk pediatric cancer', Cancer Biology and Therapy, vol. 19, pp. 1078 - 1087, http://dx.doi.org/10.1080/15384047.2018.1491498

Ziegler DS; Wong M; Mayoh C; Kumar A; Tsoli M; Mould E; Tyrrell V; Khuong-Quang DA; Pinese M; Gayevskiy V, 2018, 'Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma', British Journal of Cancer, vol. 119, pp. 693 - 696, http://dx.doi.org/10.1038/s41416-018-0251-2

Ooi CY; Carter DR; Liu B; Mayoh C; Beckers A; Lalwani A; Nagy Z; De Brouwer S; Decaesteker B; Hung TT, 2018, 'Network modeling of microRNA-mRNA interactions in neuroblastoma tumorigenesis identifies miR-204 as a direct inhibitor of MYCN', Cancer Research, vol. 78, pp. 3122 - 3134, http://dx.doi.org/10.1158/0008-5472.CAN-17-3034

Fletcher JI; Ziegler DS; Trahair TN; Marshall GM; Haber M; Norris MD, 2018, 'Too many targets, not enough patients: Rethinking neuroblastoma clinical trials', Nature Reviews Cancer, vol. 18, pp. 389 - 400, http://dx.doi.org/10.1038/s41568-018-0003-x

Ferrucci F; Ciaccio R; Monticelli S; Pigini P; di Giacomo S; Purgato S; Erriquez D; Bernardoni R; Norris M; Haber M, 2018, 'MAX to MYCN intracellular ratio drives the aggressive phenotype and clinical outcome of high risk neuroblastoma', Biochimica et Biophysica Acta - Gene Regulatory Mechanisms, vol. 1861, pp. 235 - 245, http://dx.doi.org/10.1016/j.bbagrm.2018.01.007

Sutton R; Venn NC; Law T; Boer JM; Trahair TN; Ng A; Den Boer ML; Dissanayake A; Giles JE; Dalzell P, 2018, 'A risk score including microdeletions improves relapse prediction for standard and medium risk precursor B-cell acute lymphoblastic leukaemia in children', British Journal of Haematology, vol. 180, pp. 550 - 562, http://dx.doi.org/10.1111/bjh.15056

Burchill SA; Beiske K; Shimada H; Ambros PF; Seeger R; Tytgat GAM; Brock PR; Haber M; Park JR; Berthold F, 2017, 'Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Workin', Cancer, vol. 123, pp. 1095 - 1105, http://dx.doi.org/10.1002/cncr.30380

Murray J; Valli E; Yu DMT; Truong AM; Gifford AJ; Eden GL; Gamble LD; Hanssen KM; Flemming CL; Tan A, 2017, 'Suppression of the ATP-binding cassette transporter ABCC4 impairs neuroblastoma tumour growth and sensitises to irinotecan in vivo', European Journal of Cancer, vol. 83, pp. 132 - 141, http://dx.doi.org/10.1016/j.ejca.2017.06.024

Dagg RA; Pickett HA; Neumann AA; Napier CE; Henson JD; Teber ET; Arthur JW; Reynolds CP; Murray J; Haber M, 2017, 'Extensive Proliferation of Human Cancer Cells with Ever-Shorter Telomeres', Cell Reports, vol. 19, pp. 2544 - 2556, http://dx.doi.org/10.1016/j.celrep.2017.05.087

Jung MS; Russell AJ; Liu B; George J; Liu PY; Liu T; DeFazio A; Bowtell DDL; Oberthuer A; London WB, 2017, 'A Myc activity signature predicts poor clinical outcomes in Myc-associated cancers', Cancer Research, vol. 77, pp. 971 - 981, http://dx.doi.org/10.1158/0008-5472.CAN-15-2906

Liu PY; Sokolowski N; Guo ST; Siddiqi F; Atmadibrata B; Telfer TJ; Sun Y; Zhang L; Yu D; Mccarroll J, 2016, 'The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs', Oncotarget, vol. 7, pp. 79217 - 79232, http://dx.doi.org/10.18632/oncotarget.12640

Evageliou NF; Haber M; Vu A; Laetsch TW; Murray J; Gamble LD; Cheng NC; Liu K; Reese M; Corrigan KA, 2016, 'Polyamine antagonist therapies inhibit neuroblastoma initiation and progression', Clinical Cancer Research, vol. 22, pp. 4391 - 4404, http://dx.doi.org/10.1158/1078-0432.CCR-15-2539

Xue C; Yu DMT; Gherardi S; Koach J; Milazzo G; Gamble L; Liu B; Valli E; Russell AJ; London WB, 2016, 'MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4', Oncotarget, vol. 7, pp. 54937 - 54951, http://dx.doi.org/10.18632/oncotarget.10709

French JD; Johnatty SE; Lu Y; Beesley J; Gao B; Kalimutho M; Henderson MJ; Russell AJ; Kar S; Chen X, 2016, 'Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer', Oncotarget, vol. 7, pp. 6353 - 6368, http://dx.doi.org/10.18632/oncotarget.7047

Vittorio O; Brandl M; Cirillo G; Kimpton K; Hinde E; Gaus K; Yee E; Kumar N; Duong H; Fleming C, 2016, 'Dextran-Catechin: An anticancer chemically-modified natural compound targeting copper that attenuates neuroblastoma growth', Oncotarget, vol. 7, pp. 47479 - 47493, http://dx.doi.org/10.18632/oncotarget.10201

Somers K; Chudakova DA; Middlemiss SMC; Wen VW; Clifton M; Kwek A; Liu B; Mayoh C; Bongers A; Karsa M, 2016, 'CCI-007, a novel small molecule with cytotoxic activity against infant leukemia with MLL rearrangements', Oncotarget, vol. 7, pp. 46067 - 46087, http://dx.doi.org/10.18632/oncotarget.10022

O'Brien R; Tran SL; Maritz MF; Liu B; Kong CF; Purgato S; Yang C; Murray J; Russell AJ; Flemming CL, 2016, 'MYC-driven neuroblastomas are addicted to a telomerase-independent function of dyskerin', Cancer Research, vol. 76, pp. 3604 - 3617, http://dx.doi.org/10.1158/0008-5472.CAN-15-0879

Fletcher JI; Williams RT; Henderson MJ; Norris MD; Haber M, 2016, 'ABC transporters as mediators of drug resistance and contributors to cancer cell biology', Drug Resistance Updates, vol. 26, pp. 1 - 9, http://dx.doi.org/10.1016/j.drup.2016.03.001

Tee AE; Liu B; Song R; Li J; Pasquier E; Cheung BB; Jiang C; Marshall GM; Haber M; Norris MD, 2016, 'The long noncoding RNA MALAT1 promotes tumor-driven angiogenesis by up-regulating pro-angiogenic gene expression', Oncotarget, vol. 7, pp. 8663 - 8675, http://dx.doi.org/10.18632/oncotarget.6675

Carter DR; Sutton SK; Pajic M; Murray J; Sekyere EO; Fletcher J; Beckers A; De Preter K; Speleman F; George RE, 2016, 'Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis', Molecular Oncology, vol. 10, pp. 866 - 878, http://dx.doi.org/10.1016/j.molonc.2016.02.004

Kim PY; Tan O; Liu B; Trahair T; Liu T; Haber M; Norris MD; Marshall GM; Cheung BB, 2016, 'High TDP43 expression is required for TRIM16-induced inhibition of cancer cell growth and correlated with good prognosis of neuroblastoma and breast cancer patients', Cancer Letters, vol. 374, pp. 315 - 323, http://dx.doi.org/10.1016/j.canlet.2016.02.021

Lynch JR; Yi H; Casolari DA; Voli F; Gonzales-Aloy E; Fung TK; Liu B; Brown A; Liu T; Haber M, 2016, 'Gaq signaling is required for the maintenance of MLL-AF9-induced acute myeloid leukemia', Leukemia, vol. 30, pp. 1745 - 1748, http://dx.doi.org/10.1038/leu.2016.24

Decock A; Ongenaert M; Cannoodt R; Verniers K; Wilde BD; Laureys G; Van Roy N; Berbegall AP; Bienertova-Vasku J; Bown N, 2016, 'Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma', Oncotarget, vol. 7, pp. 1960 - 1972, http://dx.doi.org/10.18632/oncotarget.6477

Bassiri H; Benavides A; Haber M; Gilmour SK; Norris MD; Hogarty MD, 2015, 'Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma.', Transl Pediatr, vol. 4, pp. 226 - 238, http://dx.doi.org/10.3978/j.issn.2224-4336.2015.04.06

Carter DR; Murray J; Cheung BB; Gamble L; Koach J; Tsang J; Sutton S; Kalla H; Syed S; Gifford AJ, 2015, 'Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma', Science Translational Medicine, vol. 7, http://dx.doi.org/10.1126/scitranslmed.aab1803

Greenop KR; Scott RJ; Attia J; Bower C; De Klerk NH; Norris MD; Haber M; Jamieson SE; Van Bockxmeer FM; Gottardo NG, 2015, 'Folate pathway gene polymorphisms and risk of childhood brain tumors: Results from an Australian case-control study', Cancer Epidemiology Biomarkers and Prevention, vol. 24, pp. 931 - 937, http://dx.doi.org/10.1158/1055-9965.EPI-14-1248

Lau DT; Flemming CL; Gherardi S; Perini G; Oberthuer A; Fischer M; Juraeva D; Brors B; Xue C; Norris MD, 2015, 'MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma', Oncotarget, vol. 6, pp. 15510 - 15523, http://dx.doi.org/10.18632/oncotarget.3732

Milne E; Greenop KR; Scott RJ; Haber M; Norris MD; Attia J; Jamieson SE; Miller M; Bower C; Bailey HD, 2015, 'Folate pathway gene polymorphisms, maternal folic acid use, and risk of childhood acute lymphoblastic leukemia', Cancer Epidemiology Biomarkers and Prevention, vol. 24, pp. 48 - 56, http://dx.doi.org/10.1158/1055-9965.EPI-14-0680

Sutton R; Shaw PJ; Venn NC; Law T; Dissanayake A; Kilo T; Haber M; Norris MD; Fraser C; Alvaro F, 2015, 'Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia', British Journal of Haematology, vol. 168, pp. 395 - 404, http://dx.doi.org/10.1111/bjh.13142

Yu DMT; Huynh T; Truong AM; Haber M; Norris MD, 2015, 'ABC Transporters and Neuroblastoma', Advances in Cancer Research, http://dx.doi.org/10.1016/bs.acr.2014.10.005

Cheung BB; Tan O; Koach J; Liu B; Shum MSY; Carter DR; Sutton S; Po'uha ST; Chesler L; Haber M, 2014, 'Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma', Molecular Oncology, http://dx.doi.org/10.1016/j.molonc.2015.04.005

Dietrich PA; Yang C; Leung HHL; Lynch JR; Gonzales E; Liu B; Haber M; Norris MD; Wang J; Wang JY, 2014, 'GPR84 sustains aberrant β-catenin signaling in leukemic stem cells for maintenance of MLL leukemogenesis', Blood, vol. 124, pp. 3284 - 3294, http://dx.doi.org/10.1182/blood-2013-10-532523

Gao B; Russell A; Beesley J; Chen XQ; Healey S; Henderson M; Wong M; Emmanuel C; Galletta L; Johnatty SE, 2014, 'Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer.', Scientific reports, vol. 4, pp. 4669, http://dx.doi.org/10.1038/srep04669

Dorstyn L; Puccini J; Nikolic A; Shalini S; Wilson CH; Norris MD; Haber M; Kumar S, 2014, 'An unexpected role for caspase-2 in neuroblastoma', Cell Death and Disease, vol. 5, http://dx.doi.org/10.1038/cddis.2014.342

Hedditch EL; Gao B; Russell AJ; Lu Y; Emmanuel C; Beesley J; Johnatty SE; Chen X; Harnett P; George J, 2014, 'ABCA transporter gene expression and poor outcome in epithelial ovarian cancer', Journal of the National Cancer Institute, vol. 106, http://dx.doi.org/10.1093/jnci/dju149

Shahbazi J; Scarlett CJ; Norris MD; Liu B; Haber M; Tee AE; Carrier A; Biankin AV; London WB; Marshall GM, 2014, 'Histone Deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1', Oncotarget, vol. 5, pp. 4257 - 4268, http://dx.doi.org/10.18632/oncotarget.1991

Saletta F; Wadham C; Ziegler DS; Marshall GM; Haber M; McCowage G; Norris MD; Byrne JA, 2014, 'Molecular profiling of childhood cancer: Biomarkers and novel therapies', BBA Clinical, vol. 1, pp. 59 - 77, http://dx.doi.org/10.1016/j.bbacli.2014.06.003

Cheung L; Flemming CL; Watt F; Masada N; Yu DMT; Huynh T; Conseil G; Tivnan A; Polinsky A; Gudkov AV, 2014, 'High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4).', Biochem Pharmacol, vol. 91, pp. 97 - 108, http://dx.doi.org/10.1016/j.bcp.2014.05.023

Tee AE; Ling D; Nelson C; Atmadibrata B; Dinger ME; Xu N; Mizukami T; Liu PY; Liu B; Cheung B, 2014, 'The histone demethylase JMJD1A induces cell migration and invasion by up-regulating the expression of the long noncoding RNA MALAT1', Oncotarget, vol. 5, pp. 1793 - 1804, http://dx.doi.org/10.18632/oncotarget.1785

Kim PY; Tan O; Diakiw SM; Carter D; Sekerye EO; Wasinger VC; Liu T; Kavallaris M; Norris MD; Haber M, 2014, 'Identification of plasma Complement C3 as a potential biomarker for neuroblastoma using a quantitative proteomic approach', Journal of Proteomics, vol. 96, pp. 1 - 12, http://dx.doi.org/10.1016/j.jprot.2013.10.032

Burkhart CA; Haber M; Norris MD; Gudkov AV; Nikiforov MA, 2013, 'Cell-based methods for the identification of Myc-inhibitory small molecules', Methods in Molecular Biology, vol. 1012, pp. 255 - 264, http://dx.doi.org/10.1007/978-1-62703-429-6_18

Karsa M; Dalla Pozza L; Venn NC; Law T; Shi R; Giles JE; Bahar AY; Cross S; Catchpoole D; Haber M, 2013, 'Improving the identification of high risk precursor B acute lymphoblastic leukemia patients with earlier quantification of minimal residual disease.', PLoS One, vol. 8, pp. e76455, http://dx.doi.org/10.1371/journal.pone.0076455

Johnatty SE; Beesley J; Gao B; Chen X; Lu Y; Law MH; Henderson MJ; Russell AJ; Hedditch EL; Emmanuel C, 2013, 'ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: A comprehensive analysis from the Ovarian Cancer Association Consortium and the Cancer Genome Atlas', Gynecologic Oncology, vol. 131, pp. 8 - 14, http://dx.doi.org/10.1016/j.ygyno.2013.07.107

Kim PY; Rahmanto AS; Tan O; Norris MD; Haber M; Marshall GM; Cheung BB, 2013, 'TRIM16 overexpression induces apoptosis through activation of caspase-2 in cancer cells', Apoptosis, vol. 18, pp. 639 - 651, http://dx.doi.org/10.1007/s10495-013-0813-y

Marshall GM; Dalla Pozza L; Sutton R; Ng A; De Groot-Kruseman HA; Van Der Velden VH; Venn NC; Van Den Berg H; De Bont ESJM; Maarten Egeler R, 2013, 'High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation', Leukemia, vol. 27, pp. 1497 - 1503, http://dx.doi.org/10.1038/leu.2013.44

Liu PY; Xu N; Malyukova A; Scarlett CJ; Sun YT; Zhang XD; Ling D; Su SP; Nelson C; Chang DK, 2013, 'The histone deacetylase SIRT2 stabilizes Myc oncoproteins', Cell Death and Differentiation, vol. 20, pp. 503 - 514, http://dx.doi.org/10.1038/cdd.2012.147

Malyukova A; Brown S; Papa R; O'Brien R; Giles J; Trahair TN; Dalla Pozza L; Sutton R; Liu T; Haber M, 2013, 'FBXW7 regulates glucocorticoid response in T-cell acute lymphoblastic leukaemia by targeting the glucocorticoid receptor for degradation', Leukemia, vol. 27, pp. 1053 - 1062, http://dx.doi.org/10.1038/leu.2012.361

Calao M; Sekyere EO; Cui HJ; Cheung BB; Thomas WD; Keating J; Chen JB; Raif A; Jankowski K; Davies NP, 2013, 'Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation', Oncogene, vol. 32, pp. 3616 - 3626, http://dx.doi.org/10.1038/onc.2012.368

Lau DT; Hesson LB; Norris MD; Haber M; Marshall GM; Ashton LJ, 2012, 'Prognostic significance of promoter DNA methylation in patients with neuroblastoma', CANCER RESEARCH, vol. 72, http://dx.doi.org/10.1158/1538-7445.AM2012-1425

Gamble LD; Hogarty MD; Liu X; Ziegler DS; Marshall G; Norris MD; Haber M, 2012, 'Polyamine pathway inhibition as a novel therapeutic approach to treating neuroblastoma.', Front Oncol, vol. 2, pp. 162, http://dx.doi.org/10.3389/fonc.2012.00162

Huynh T; Norris MD; Haber M; Henderson MJ, 2012, 'ABCC4/MRP4: a MYCN-regulated transporter and potential therapeutic target in neuroblastoma.', Front Oncol, vol. 2, pp. 178, http://dx.doi.org/10.3389/fonc.2012.00178

Venn NC; Van Der Velden VHJ; De Bie M; Waanders E; Giles JE; Law T; Kuiper RP; De Haas V; Mullighan CG; Haber M, 2012, 'Highly sensitive MRD tests for ALL based on the IKZF1 Δ3-6 microdeletion', Leukemia, vol. 26, pp. 1414 - 1416, http://dx.doi.org/10.1038/leu.2011.348

Fletcher JI; Gherardi S; Murray J; Burkhart CA; Russell A; Valli E; Smith J; Oberthuer A; Ashton LJ; London WB, 2012, 'N-Myc regulates expression of the detoxifying enzyme glutathione transferase GSTP1, a marker of poor outcome in neuroblastoma', Cancer Research, vol. 72, pp. 845 - 853, http://dx.doi.org/10.1158/0008-5472.CAN-11-1885

Schleiermacher G; Mosseri V; London WB; Maris JM; Brodeur GM; Attiyeh E; Haber M; Khan J; Nakagawara A; Speleman F, 2012, 'Segmental chromosomal alterations have prognostic impact in neuroblastoma: A report from the INRG project', British Journal of Cancer, vol. 107, pp. 1418 - 1422, http://dx.doi.org/10.1038/bjc.2012.375

Lau DT; Hesson LB; Norris MD; Marshall GM; Haber M; Ashton LJ, 2012, 'Prognostic significance of promoter DNA methylation in patients with childhood neuroblastoma', Clinical Cancer Research, vol. 18, pp. 5690 - 5700, http://dx.doi.org/10.1158/1078-0432.CCR-12-0294

Keating J; Tsoli M; Hallahan AR; Ingram WJ; Haber M; Ziegler DS, 2012, 'Targeting the inhibitor of apoptosis proteins as a novel therapeutic strategy in medulloblastoma', Molecular Cancer Therapeutics, vol. 11, pp. 2654 - 2663, http://dx.doi.org/10.1158/1535-7163.MCT-12-0352

Cheung BB; Koach J; Tan O; Kim P; Bell JL; D'Andreti C; Sutton S; Malyukova A; Sekyere E; Norris M, 2012, 'The retinoid signalling molecule, TRIM16, is repressed during squamous cell carcinoma skin carcinogenesis in vivo and reduces skin cancer cell migration in vitro', Journal of Pathology, vol. 226, pp. 451 - 462, http://dx.doi.org/10.1002/path.2986

Neiron Z; Jankowski K; Murray J; Champion S; Norris MD; Haber M; Fletcher JI, 2011, 'Development of organ-selective neuroblastoma cell lines to identify genes mediating bone marrow and liver colonization', CANCER RESEARCH, vol. 71, http://dx.doi.org/10.1158/1538-7445.AM2011-5237

Porro A; Iraci N; Soverini S; Diolaiti D; Gherardi S; Terragna C; Durante S; Valli E; Kalebic T; Bernardoni R, 2011, 'c-MYC oncoprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in chronic myelogenous leukemia CD34 ⁺ hematopoietic progenitor cells', Molecular Cancer Research, vol. 9, pp. 1054 - 1066, http://dx.doi.org/10.1158/1541-7786.MCR-10-0510

Henderson MJ; Haber M; Porro A; Munoz MA; Iraci N; Xue C; Murray J; Flemming CL; Smith J; Fletcher JI, 2011, 'ABCC multidrug transporters in childhood neuroblastoma: Clinical and biological effects independent of cytotoxic drug efflux', Journal of the National Cancer Institute, vol. 103, pp. 1236 - 1251, http://dx.doi.org/10.1093/jnci/djr256

Pajic M; Murray J; Marshall GM; Cole SPC; Norris MD; Haber M, 2011, 'ABCC1 G2012T single nucleotide polymorphism is associated with patient outcome in primary neuroblastoma and altered stability of the ABCC1 gene transcript', Pharmacogenetics and Genomics, vol. 21, pp. 270 - 279, http://dx.doi.org/10.1097/FPC.0b013e328343dd5f

Marshall GM; Liu PY; Gherardi S; Scarlett CJ; Bedalov A; Xu N; Iraci N; Valli E; Ling D; Thomas W, 2011, 'SIRT1 promotes N-Myc oncogenesis through a positive feedback loop involving the effects of MKP3 and ERK on N-Myc protein stability', PLoS Genetics, vol. 7, http://dx.doi.org/10.1371/journal.pgen.1002135

Lau DT; Norris MD; Marshall GM; Haber M; Ashton LJ, 2011, 'HLA-G polymorphisms, genetic susceptibility, and clinical outcome in childhood neuroblastoma', Tissue Antigens, vol. 78, pp. 421 - 427, http://dx.doi.org/10.1111/j.1399-0039.2011.01781.x

Bhadri VA; McGregor MR; Venn NC; Hackenberg N; Russell SJ; Norris MD; Haber M; Sutton R; Marshall GM, 2010, 'Isolated testicular relapse after allo-SCT in boys with ALL: Outcome without second transplant', Bone Marrow Transplantation, vol. 45, pp. 397 - 399, http://dx.doi.org/10.1038/bmt.2009.138

Milne E; Royle JA; Miller M; Bower C; De Klerk NH; Bailey HD; Van Bockxmeer F; Attia J; Scott RJ; Norris MD, 2010, 'Maternal folate and other vitamin supplementation during pregnancy and risk of acute lymphoblastic leukemia in the offspring', International Journal of Cancer, vol. 126, pp. 2690 - 2699, http://dx.doi.org/10.1002/ijc.24969

Porro A; Haber M; Diolaiti D; Iraci N; Henderson M; Gherardi S; Valli E; Munoz MA; Xue C; Flemming C, 2010, 'Direct and coordinate regulation of ATP-binding cassette transporter genes by Myc factors generates specific transcription signatures that significantly affect the chemoresistance phenotype of cancer', Journal of Biological Chemistry, vol. 285, pp. 19532 - 19543, http://dx.doi.org/10.1074/jbc.M109.078584

Fletcher JI; Haber M; Henderson MJ; Norris MD, 2010, 'ABC transporters in cancer: More than just drug efflux pumps', Nature Reviews Cancer, vol. 10, pp. 147 - 156, http://dx.doi.org/10.1038/nrc2789

Tee AEL; Marshall GM; Liu PY; Xu N; Haber M; Norris MD; Iismaa SE; Liu T, 2010, 'Opposing effects of two tissue transglutaminase protein isoforms in neuroblastoma cell differentiation', Journal of Biological Chemistry, vol. 285, pp. 3561 - 3567, http://dx.doi.org/10.1074/jbc.M109.053041

Marshall GM; Gherardi S; Xu N; Neiron Z; Trahair T; Scarlett CJ; Chang DK; Liu PY; Jankowski K; Iraci N, 2010, 'Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects', Oncogene, vol. 29, pp. 5957 - 5968, http://dx.doi.org/10.1038/onc.2010.332

Marshall GM; Bell JL; Koach J; Tan O; Kim P; Malyukova A; Thomas W; Sekyere EO; Liu T; Cunningham AM, 2010, 'TRIM16 acts as a tumour suppressor by inhibitory effects on cytoplasmic vimentin and nuclear E2F1 in neuroblastoma cells', Oncogene, vol. 29, pp. 6172 - 6183, http://dx.doi.org/10.1038/onc.2010.340

Swarbrick A; Woods SL; Shaw A; Balakrishnan A; Phua Y; Nguyen A; Chanthery Y; Lim L; Ashton LJ; Judson RL, 2010, 'MiR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma', Nature Medicine, vol. 16, pp. 1134 - 1140, http://dx.doi.org/10.1038/nm.2227

Ambros PF; Ambros IM; Brodeur GM; Haber M; Khan J; Nakagawara A; Schleiermacher G; Speleman F; Spitz R; London WB, 2009, 'International consensus for neuroblastoma molecular diagnostics: Report from the International Neuroblastoma Risk Group (INRG) Biology Committee', British Journal of Cancer, vol. 100, pp. 1471 - 1482, http://dx.doi.org/10.1038/sj.bjc.6605014

Ashton LJ; Gifford AJ; Kwan E; Lingwood A; Lau DTT; Marshall GM; Haber M; Norris MD, 2009, 'Reduced folate carrier and methylenetetrahydrofolate reductase gene polymorphisms: Associations with clinical outcome in childhood acute lymphoblastic leukemia', Leukemia, vol. 23, pp. 1348 - 1351, http://dx.doi.org/10.1038/leu.2009.67

Sutton R; Venn NC; Tolisano J; Bahar AY; Giles JE; Ashton LJ; Teague L; Rigutto G; Waters K; Marshall GM, 2009, 'Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia', British Journal of Haematology, vol. 146, pp. 292 - 299, http://dx.doi.org/10.1111/j.1365-2141.2009.07744.x

Bohlken A; Cheung BB; Bell JL; Koach J; Smith S; Sekyere E; Thomas W; Norris M; Haber M; Lovejoy DB, 2009, 'ATP7A is a novel target of retinoic acid receptor β2 in neuroblastoma cells', British Journal of Cancer, vol. 100, pp. 96 - 105, http://dx.doi.org/10.1038/sj.bjc.6604833

Thomas WD; Chen J; Gao YR; Cheung B; Koach J; Sekyere E; Norris MD; Haber M; Ellis T; Wainwright B, 2009, 'Patched1 deletion increases N-Myc protein stability as a mechanism of medulloblastoma initiation and progression', Oncogene, vol. 28, pp. 1605 - 1615, http://dx.doi.org/10.1038/onc.2009.3

Raif A; Marshall GM; Bell JL; Koach J; Tan O; D'andreti C; Thomas W; Sekyere E; Norris M; Haber M, 2009, 'The estrogen-responsive B box protein (EBBP) restores retinoid sensitivity in retinoid-resistant cancer cells via effects on histone acetylation', Cancer Letters, vol. 277, pp. 82 - 90, http://dx.doi.org/10.1016/j.canlet.2008.11.030

Burkhart CA; Watt F; Murray J; Pajic M; Prokvolit A; Xue C; Flemming C; Smith J; Purmal A; Isachenko N, 2009, 'Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapyin mouse models of neuroblastoma', Cancer Research, vol. 69, pp. 6573 - 6580, http://dx.doi.org/10.1158/0008-5472.CAN-09-1075

Brisco MJ; Latham S; Sutton R; Hughes E; Wilczek V; Van Zanten K; Budgen B; Bahar AY; Malec M; Sykes PJ, 2009, 'Determining the repertoire of IGH gene rearrangements to develop molecular markers for minimal residual disease in B-lineage acute lymphoblastic leukemia', Journal of Molecular Diagnostics, vol. 11, pp. 194 - 200, http://dx.doi.org/10.2353/jmoldx.2009.080047

Dilda PJ; Decollogne S; Weerakoon L; Norris MD; Haber M; Allen JD; Hogg PJ, 2009, 'Optimization of the antitumor efficacy of a synthetic mitochondrial toxin by increasing the residence time in the cytosol', Journal of Medicinal Chemistry, vol. 52, pp. 6209 - 6216, http://dx.doi.org/10.1021/jm9008339

Liu T; Liu PY; Tee AEL; Haber M; Norris MD; Gleave ME; Marshall GM, 2009, 'Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors', European Journal of Cancer, vol. 45, pp. 1846 - 1854, http://dx.doi.org/10.1016/j.ejca.2009.03.002

Kuljaca S; Liu T; Dwarte T; Kavallaris M; Haber M; Norris MD; Martin-Caballero J; Marshall GM, 2009, 'The cyclin-dependent kinase inhibitor, p21^WAF1, promotes angiogenesis by repressing gene transcription of thioredoxin-binding protein 2 in cancer cells', Carcinogenesis, vol. 30, pp. 1865 - 1871, http://dx.doi.org/10.1093/carcin/bgp225

Smith DJ; Cossins LR; Hatzinisiriou I; Haber M; Nagley P, 2008, 'Lack of correlation between MYCN expression and the Warburg effect in neuroblastoma cell lines', BMC Cancer, vol. 8, http://dx.doi.org/10.1186/1471-2407-8-251

Williams BB; Wall M; Miao RY; Williams B; Bertoncello I; Kershaw MH; Mantamadiotis T; Haber M; Norris MD; Gautam A, 2008, 'Induction of T cell-mediated immunity using a c-Myb DNA vaccine in a mouse model of colon cancer', Cancer Immunology, Immunotherapy, vol. 57, pp. 1635 - 1645, http://dx.doi.org/10.1007/s00262-008-0497-2

Henderson MJ; Choi S; Beesley AH; Baker DL; Wright D; Papa RA; Murch A; Campbell LJ; Lock RB; Norris MD, 2008, 'A xenograft model of infant leukaemia reveals a complex MLL translocation', British Journal of Haematology, vol. 140, pp. 716 - 719, http://dx.doi.org/10.1111/j.1365-2141.2007.06966.x

Sutton R; Bahar AY; Kwan E; Giles JE; Venn NC; Tran S; Hackenberg N; Pozza LD; Marshall GM; Haber M, 2008, 'Improving minimal residual disease detection in precursor B-ALL based on immunoglobulin-κ and heavy-chain gene rearrangements', Leukemia, vol. 22, pp. 2265 - 2267, http://dx.doi.org/10.1038/leu.2008.121

Sutton R; Lonergan M; Tapp H; Venn NC; Haber M; Norris MD; O'Brien TA; Alvaro F; Revesz T, 2008, 'Two cases of hypereosinophilia and high-risk acute lymphoblastic leukemia', Leukemia, vol. 22, pp. 1463 - 1465, http://dx.doi.org/10.1038/sj.leu.2405096

Hogarty MD; Norris MD; Davis K; Liu X; Evageliou NF; Hayes CS; Pawel B; Guo R; Zhao H; Sekyere E, 2008, 'ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma', Cancer Research, vol. 68, pp. 9735 - 9745, http://dx.doi.org/10.1158/0008-5472.CAN-07-6866

Henderson MJ; Choi S; Beesley AH; Sutton R; Venn NC; Marshall GM; Kees UR; Haber M; Norris MD, 2008, 'Mechanism of relapse in pediatric acute lymphoblastic leukemia', Cell Cycle, vol. 7, pp. 1315 - 1320, http://dx.doi.org/10.4161/cc.7.10.5885

Munoz M; Henderson M; Haber M; Norris M, 2007, 'Role of the MRP1/ABCC1 multidrug transporter protein in cancer', IUBMB Life, vol. 59, pp. 752 - 757, http://dx.doi.org/10.1080/15216540701736285

Cheng AJ; Ching Cheng N; Ford J; Smith J; Murray JE; Flemming C; Lastowska M; Jackson MS; Hackett CS; Weiss WA, 2007, 'Cell lines from MYCN transgenic murine tumours reflect the molecular and biological characteristics of human neuroblastoma', European Journal of Cancer, vol. 43, pp. 1467 - 1475, http://dx.doi.org/10.1016/j.ejca.2007.03.008

Choi S; Henderson MJ; Kwan E; Beesley AH; Sutton R; Bahar AY; Giles J; Venn NC; Dalla Pozza L; Baker DL, 2007, 'Relapse in children with acute lymphoblastic leukemia involving selection of a preexisting drug-resistant subclone', Blood, vol. 110, pp. 632 - 639, http://dx.doi.org/10.1182/blood-2007-01-067785

Ashton LJ; Murray JE; Haber M; Marshall GM; Ashley DM; Norris MD, 2007, 'Polymorphisms in genes encoding drug metabolizing enzymes and their influence on the outcome of children with neuroblastoma', Pharmacogenetics and Genomics, vol. 17, pp. 709 - 717, http://dx.doi.org/10.1097/FPC.0b013e3280e1cc92

Xue C; Haber M; Flemming C; Marshall GM; Lock RB; MacKenzie KL; Gurova KV; Norris MD; Gudkov AV, 2007, 'p53 determines multidrug sensitivity of childhood neuroblastoma', Cancer Research, vol. 67, pp. 10351 - 10360, http://dx.doi.org/10.1158/0008-5472.CAN-06-4345

Liu T; Tee AEL; Porro A; Smith SA; Dwarte T; Pei YL; Iraci N; Sekyere E; Haber M; Norris MD, 2007, 'Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis', Proceedings of the National Academy of Sciences of the United States of America, vol. 104, pp. 18682 - 18687, http://dx.doi.org/10.1073/pnas.0705524104

Liu T; Tee AEL; Porro A; Smith SA; Dwarte T; Pei YL; Iraci N; Sekyere E; Haber M; Norris MD, 2007, 'Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis (Proceedings of the National Academy of Science of the United States', Proceedings of the National Academy of Sciences of the United States of America, vol. 104, pp. 21021, http://dx.doi.org/10.1073/pnas.0711060105

Kuljaca S; Liu T; Tee AEL; Haber M; Norris MD; Dwarte T; Marshall GM, 2007, 'Enhancing the anti-angiogenic action of histone deacetylase inhibitors', Molecular Cancer, vol. 6, http://dx.doi.org/10.1186/1476-4598-6-68

Haber M; Smith J; Bordow SB; Flemming C; Cohn SL; London WB; Marshall GM; Norris MD, 2006, 'Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma', Journal of Clinical Oncology, vol. 24, pp. 1546 - 1553, http://dx.doi.org/10.1200/JCO.2005.01.6196

Cheung BB; Bell J; Raif A; Bohlken A; Yan J; Roediger B; Poljak A; Smith S; Lee M; Thomas WD, 2006, 'The estrogen-responsive B box protein is a novel regulator of the retinoid signal', Journal of Biological Chemistry, vol. 281, pp. 18246 - 18256, http://dx.doi.org/10.1074/jbc.M600879200

Norris MD; Smith J; Tanabe K; Tobin P; Flemming C; Scheffer GL; Wielinga P; Cohn SL; London WB; Marshall GM, 2005, 'Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro', Molecular Cancer Therapeutics, vol. 4, pp. 547 - 553, http://dx.doi.org/10.1158/1535-7163.MCT-04-0161

Liu T; Bohlken A; Kuljaca S; Lee M; Nguyen T; Smith S; Cheung B; Morris MD; Haber M; Holloway AJ, 2005, 'The retinoid anticancer signal: Mechanisms of target gene regulation', British Journal of Cancer, vol. 93, pp. 310 - 318, http://dx.doi.org/10.1038/sj.bjc.6602700

Laughton SJ; Ashton LJ; Kwan E; Norris MD; Haber M; Marshall GM, 2005, 'Early responses to chemotherapy of normal and malignant hematologic cells are prognostic in children with acute lymphoblastic leukemia', Journal of Clinical Oncology, vol. 23, pp. 2264 - 2271, http://dx.doi.org/10.1200/JCO.2005.04.012

Pajic M; Norris MD; Cohn SL; Haber M, 2005, 'The role of the multidrug resistance-associated protein 1 gene in neuroblastoma biology and clinical outcome', Cancer Letters, vol. 228, pp. 241 - 246, http://dx.doi.org/10.1016/j.canlet.2005.01.060

Norris MD; Smith J; Tanabe K; Tobin P; Flemming C; Scheffer G; Wielinga P; Cohn SL; London WB; Marshall GM, 2005, 'Expression of multi-drug transport MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro', Molecular Cancer Therapeutics, vol. 4, pp. 547 - 553

Łastowska M; Chung YJ; Ching NC; Haber M; Norris MD; Kees UR; Pearson ADJ; Jackson MS, 2004, 'Regions Syntenic to Human 17q Are Gained in Mouse and Rat Neuroblastoma', Genes Chromosomes and Cancer, vol. 40, pp. 158 - 163, http://dx.doi.org/10.1002/gcc.20031

Manohar CF; Bray JA; Salwen HR; Madafiglio J; Cheng A; Flemming C; Marshall GM; Norris MD; Haber M; Cohn SL, 2004, 'MYCN-mediated regulation of the MRP1 promoter in human neuroblastoma', Oncogene, vol. 23, pp. 753 - 762, http://dx.doi.org/10.1038/sj.onc.1207151

Hansford LM; Thomas WD; Keating JM; Burkhart CA; Peaston AE; Norris MD; Haber M; Armati PJ; Weiss WA; Marshall GM, 2004, 'Mechanisms of embryonal tumor initiation: Distinct roles for MycN expression and MYCN amplification', Proceedings of the National Academy of Sciences of the United States of America, vol. 101, pp. 12664 - 12669, http://dx.doi.org/10.1073/pnas.0401083101

Don S; Verrills NM; Liaw TYE; Liu MLM; Norris MD; Haber M; Kavallaris M, 2004, 'Neuronal-associated microtubule proteins class III β-tubulin ad MAP2c in neuroblastoma: Role in resistance to microtubule-targeted drugs', Molecular Cancer Therapeutics, vol. 3, pp. 1137 - 1146

Liem NLM; Papa RA; Milross CG; Schmid MA; Tajbakhsh M; Choi S; Ramirez CD; Rice AM; Haber M; Norris MD, 2004, 'Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies', Blood, vol. 103, pp. 3905 - 3914, http://dx.doi.org/10.1182/blood-2003-08-2911

Tweddle DA; Pearson ADJ; Haber M; Norris MD; Xue C; Flemming C; Lunec J, 2003, 'The p53 pathway and its inactivation in neuroblastoma', Cancer Letters, vol. 197, pp. 93 - 98, http://dx.doi.org/10.1016/S0304-3835(03)00088-0

Marshall GM; Haber M; Kwan E; Zhu L; Ferrara D; Xue C; Brisco MJ; Sykes PJ; Morley A; Webster B, 2003, 'Importance of minimal residual disease testing during the second year of therapy for children with acute lymphoblastic leukemia', Journal of Clinical Oncology, vol. 21, pp. 704 - 709, http://dx.doi.org/10.1200/JCO.2003.10.080

Nguyen T; Hocker JE; Thomas W; Smith SA; Norris MD; Haber M; Cheung B; Marshall GM, 2003, 'Combined RARα- and RXR-specific ligands overcome N-myc-associated retinoid resistance in neuroblastoma cells', Biochemical and Biophysical Research Communications, vol. 302, pp. 462 - 468, http://dx.doi.org/10.1016/S0006-291X(03)00177-3

Hansford LM; Smith SA; Haber M; Norris MD; Cheung B; Marshall GM, 2003, 'Cloning and characterization of the human neural cell adhesion molecule, CNTN4 (alias BIG-2)', Cytogenetic and Genome Research, vol. 101, pp. 17 - 23, http://dx.doi.org/10.1159/000073412

Verrills NM; Flemming CL; Liu M; Ivery MT; Cobon GS; Norris MD; Haber M; Kavallaris M, 2003, 'Microtubule alterations and mutations induced by desoxyepothilone B: Implications for drug-target interactions', Chemistry and Biology, vol. 10, pp. 597 - 607, http://dx.doi.org/10.1016/S1074-5521(03)00141-8

Cheung B; Yan J; Smith SA; Nguyen T; Lee M; Kavallaris M; Norris MD; Haber M; Marshall GM, 2003, 'Growth inhibitory retinoid effects after recruitment of retinoid X receptor β to the retinoic acid receptor β promoter', International Journal of Cancer, vol. 105, pp. 856 - 867, http://dx.doi.org/10.1002/ijc.11153

Burkhart CA; Cheng AJ; Madafiglio J; Kavallaris M; Mili M; Marshall GM; Weiss WA; Khachigian LM; Norris MD; Haber M, 2003, 'Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma', Journal of the National Cancer Institute, vol. 95, pp. 1394 - 1403, http://dx.doi.org/10.1093/jnci/djg045

Efferth T; Verdorfer I; Miyachi H; Sauerbrey A; Drexler HG; Chitambar CR; Haber M; Gebhart E, 2002, 'Genomic imbalances in drug-resistant T-cell acute lymphoblastic CEM leukemia cell lines', Blood cells, molecules & diseases, vol. 29, pp. 1 - 13, http://dx.doi.org/10.1006/bcmd.2002.0530

Burkhart CA; Norris MD; Haber M, 2002, 'A simple method for the isolation of genomic DNA from mouse tail free of real-time PCR inhibitors', Journal of Biochemical and Biophysical Methods, vol. 52, pp. 145 - 149, http://dx.doi.org/10.1016/S0165-022X(02)00052-0

Gifford AJ; Haber M; Witt TL; Whetstine JR; Taub JW; Matherly LH; Norris MD, 2002, 'Role of the E45K-reduced folate carrier gene mutation in methotrexate resistance in human leukemia cells', Leukemia, vol. 16, pp. 2379 - 2387, http://dx.doi.org/10.1038/sj.leu.2402655

Lock RB; Liem N; Farnsworth ML; Milross CG; Xue C; Tajbakhsh M; Haber M; Norris MD; Marshall GM; Rice AM, 2002, 'The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relaps', Blood, vol. 99, pp. 4100 - 4108, http://dx.doi.org/10.1182/blood.V99.11.4100

Houghton PJ; Adamson PC; Blaney S; Fine HA; Gorlick R; Haber M; Helman L; Hirschfeld S; Hollingshead MG; Israel MA, 2002, 'Testing of new agents in childhood cancer preclinical models: Meeting summary', Clinical Cancer Research, vol. 8, pp. 3646 - 3657

Norris MD; Gilbert J; Smith SA; Marshall GM; Salwen H; Cohn SL; Haber M, 2001, 'Expression of the putative tumour suppressor gene, p73, in neuroblastoma and other childhood tumours', Medical and Pediatric Oncology, vol. 36, pp. 48 - 51, http://dx.doi.org/10.1002/1096-911X(20010101)36:1<48::AID-MPO1013>3.0.CO;2-8

Whetstine JR; Gifford AJ; Witt T; Liu XY; Flatley RM; Norris M; Haber M; Taub JW; Ravindranath Y; Matherly LH, 2001, 'Single nucleotide polymorphisms in the human reduced folate carrier: Characterization of a high-frequency G/A variant at position 80 and transport properties of the His²⁷ and Arg^{27Clinical Cancer Research, vol. 7, pp. 3416 - 3422}

Ekert H; Vivekanandan S; Chow CW; Marshall G; Haber M; Norris M; Ashley DM, 2001, 'Expression of GAGE genes in neuroblastoma by reverse transcription - Polymerase chain reaction', Cancer Research, Therapy and Control, vol. 11, pp. 197 - 203

Norris MD; Madafiglio J; Gilbert J; Marshall GM; Haber M, 2001, 'Reversal of multidrug resistance-associated protein-mediated drug resistance in cultured human neuroblastoma cells by the quinolone antibiotic difloxacin.', Med Pediatr Oncol, vol. 36, pp. 177 - 180, http://dx.doi.org/10.1002/1096-911X(20010101)36:1<177::AID-MPO1042>3.0.CO;2-Q

Norris MD; Gilbert J; Smith SA; Marshall GM; Salwen H; Cohn SL; Haber M, 2001, 'Expression of the putative tumour suppressor gene, p73, in neuroblastoma and other childhood tumours.', Med Pediatr Oncol, vol. 36, pp. 48 - 51, http://dx.doi.org/10.1002/1096-911X(20010101)36:1<48::AID-MPO1013>3.0.CO;2-8

Norris MD; Gilbert J; Smith SA; Marshall GM; Salwen H; Cohn SL; Haber M, 2001, 'Genomic and allelic expression status of the p73 gene in human neuroblastoma', Medical and Pediatric Oncology, vol. 36, pp. 45 - 47, http://dx.doi.org/10.1002/1096-911X(20010101)36:1<45::AID-MPO1012>3.0.CO;2-E

Norris MD; Madafiglio J; Gilbert J; Marshall GM; Haber M, 2001, 'Relationship between histopathological features, MYCN amplification, and prognosis: A UKCCSG study', Medical and Pediatric Oncology, vol. 36, pp. 169 - 176, http://dx.doi.org/10.1002/1096-911X(20010101)36:1<169::AID-MPO1041>3.0.CO;2-U

Lal A; Kwan E; Haber M; Norris MD; Marshall GM, 2001, 'Detection of minimal residual disease in peripheral blood prior to clinical relapse of childhood acute lymphoblastic leukaemia using PCR', Molecular and Cellular Probes, vol. 15, pp. 99 - 103, http://dx.doi.org/10.1006/mcpr.2001.0348

Peaston AE; Gardaneh M; Franco AV; Hocker JE; Murphy KM; Farnsworth ML; Catchpoole DR; Haber M; Norris MD; Lock RB, 2001, 'MRP1 gene expression level regulates the death and differentiation response of neuroblastoma cells', British Journal of Cancer, vol. 85, pp. 1564 - 1571, http://dx.doi.org/10.1054/bjoc.2001.2144

Kavallaris M; Tait AS; Norris MD; Haber M; Walsh BJ; He L; Horwitz SB, 2001, 'Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells', Cancer Research, vol. 61, pp. 5803 - 5809

Catts VS; Farnsworth ML; Haber M; Norris MD; Lutze-Mann LH; Lock RB, 2001, 'High level resistance to glucocorticoids, associated with a dysfunctional glucocorticoid receptor, in childhood acute lymphoblastic leukemia cells selected for methotrexate resistance', Leukemia, vol. 15, pp. 929 - 935, http://dx.doi.org/10.1038/sj.leu.2402128

Norris MD; Marshall GM; Haber M; Gilbert J; Madafiglio J, 2001, 'Reversal of MRP-mediated drug resistance in cultured human neuroblastome cells by the quinlone antibiotic, difloxacin', Medical Pediatric Oncology, pp. 177 - 180

Gardaneh M; Gilbert J; Haber M; Norris MD; Cohn SL; Schmidt ML; Marshall GM, 2000, 'Synergy between 5' and 3' flanking regions of the human tyrosine hydroxylase gene ensures specific, high-level expression in neuroblastoma cells', Neuroscience Letters, vol. 292, pp. 147 - 150, http://dx.doi.org/10.1016/S0304-3940(00)01474-9

Kwan E; Norris MD; Zhu L; Ferrara D; Marshall GM; Haber M, 2000, 'Simultaneous detection and quantification of minimal residual disease in childhood acute lymphoblastic leukaemia using real-time polymerase chain reaction', British Journal of Haematology, vol. 109, pp. 430 - 434, http://dx.doi.org/10.1046/j.1365-2141.2000.02029.x

Norris MD; Burkhart CA; Marshall GM; Weiss WA; Haber M, 2000, 'Expression of N-myc and MRP genes and their relationship to N-myc gene dosage and tumor formation in a murine neuroblastoma model', Medical and Pediatric Oncology, vol. 35, pp. 585 - 589, http://dx.doi.org/10.1002/1096-911X(20001201)35:6<585::AID-MPO20>3.0.CO;2-P

Cohn SL; London WB; Huang D; Katzenstein HM; Salwen HR; Reinhart T; Madafiglio J; Marshall GM; Norris MD; Haber M, 2000, 'MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN', Journal of Clinical Oncology, vol. 18, pp. 3604 - 3613, http://dx.doi.org/10.1200/JCO.2000.18.21.3604

Gilbert J; Haber M; Bordow SB; Marshall GM; Norris MD, 1999, 'Use of tumor-specific gene expression for the differential diagnosis of neuroblastoma from other pediatric small round-cell malignancies', American Journal of Pathology, vol. 155, pp. 17 - 21, http://dx.doi.org/10.1016/S0002-9440(10)65093-6

Marshall GM; Haber M; Kwan E; Zhou L; Ferrara D; Williams S; Brisco MJ; Morley A; Webster B; Dalla Pozza L, 1999, 'The effect of late intensification of therapy in children with acute lymphoblastic leukaemia and minimal residual disease.', BLOOD, vol. 94, pp. 658A - 658A, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000083790302970&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Haber M; Bordow SB; Gilbert J; Madafiglio J; Kavallaris M; Marshall GM; Mechetner EB; Fruehauf JP; Tee L; Cohn SL, 1999, 'Altered expression of the MYCN oncogene modulates MRP gene expression and response to cytotoxic drugs in neuroblastoma cells', Oncogene, vol. 18, pp. 2777 - 2782, http://dx.doi.org/10.1038/sj.onc.1202859

Peaston AE; CaMacHo ML; Norris MD; Haber M; Marsh DJ; Robinson BG; Hyland VJ; Marshall GM, 1998, 'Absence of MEN2A- or 2B-type RET mutations in primary neuroblastoma tumour tissue', Molecular and Cellular Probes, vol. 12, pp. 239 - 242, http://dx.doi.org/10.1006/mcpr.1998.0181

Cheung B; Hocker JE; Smith SA; Norris MD; Haber M; Marshall GM, 1998, 'Favorable prognostic significance of high-level retinoic acid receptor β expression in neuroblastoma mediated by effects on cell cycle regulation', Oncogene, vol. 17, pp. 751 - 759, http://dx.doi.org/10.1038/sj.onc.1201982

Bordow SB; Norris MD; Haber PS; Marshall GM; Haber M, 1998, 'Prognostic significance of MYCN oncogene expression in childhood neuroblastoma', Journal of Clinical Oncology, vol. 16, pp. 3286 - 3294, http://dx.doi.org/10.1200/JCO.1998.16.10.3286

Lal A; Kwan E; Al Mahr M; Zhou L; Ferrara D; Tobias V; O'Gorman Hughes D; Haber M; Norris MD; Marshall GM, 1998, 'Molecular detection of acute lymphoblastic leukaemia in boys with testicular relapse', Journal of Clinical Pathology - Molecular Pathology, vol. 51, pp. 277 - 281, http://dx.doi.org/10.1136/mp.51.5.277

Kavallaris M; Gardaneh M; Cheung B; Camacho ML; Hocker JE; Norris MD; Haber M; Marshall GM, 1998, 'In vitro effects of MYCN sense and antisense expression in MYCN-amplified human neuroblastoma cells', Anticancer Research, vol. 18, pp. 1793 - 1797

Gifford AJ; Kavallaris M; Madafiglio J; Matherly LH; Stewart BW; Haber M; Norris MD, 1998, 'P-glycoprotein-mediated methotrexate resistance in CCRF-CEM sublines deficient in methotrexate accumulation due to a point mutation in the reduced folate carrier gene', International Journal of Cancer, vol. 78, pp. 176 - 181, http://dx.doi.org/10.1002/(SICI)1097-0215(19981005)78:2<176::AID-IJC10>3.0.CO;2-9

Castleberry RP; Pritchard J; Ambros P; Berthold F; Brodeur GM; Castel V; Cohn SL; De Bernardi B; Dicks-Mireaux C; Frappaz D, 1997, 'The international neuroblastoma risk groups (INRG): A preliminary report', European Journal of Cancer, vol. 33, pp. 2113 - 2116, http://dx.doi.org/10.1016/S0959-8049(97)00202-5

Kwan E; Zhu L; Ferrara D; Marshall GM; Haber M; Norris MD, 1997, 'Improved PCR assay for the detection of antigen receptor gene rearrangements', Journal of Biochemical and Biophysical Methods, vol. 36, pp. 3 - 10, http://dx.doi.org/10.1016/S0165-022X(97)00043-2

Gilbert J; Norris MD; Marshall GM; Haber M, 1997, 'Low specificity of PGP9.5 expression for detection of micrometastatic neuroblastoma', British Journal of Cancer, vol. 75, pp. 1779 - 1781, http://dx.doi.org/10.1038/bjc.1997.303

Haber M; Kwan E; Zhu L; Marshall GM; Norris MD, 1997, 'Sensitive non-radioactive PCR detection of clonal T-cell receptor-gamma gene rearrangements in childhood acute lymphoblastic leukaemia', British Journal of Haematology, vol. 98, pp. 995 - 998, http://dx.doi.org/10.1046/j.1365-2141.1997.3243143.x

Marshall GM; Peaston AE; Hocker JE; Smith SA; Hansford LM; Tobias V; Norris MD; Haber M; Smith DP; Lorenzo MJ, 1997, 'Expression of multiple endocrine neoplasia 2B RET in neuroblastoma cells alters cell adhesion in Vitro, enhances metastatic behavior in Vivo, and activates Jun kinase', Cancer Research, vol. 57, pp. 5399 - 5405

Kavallaris M; Kuo DYS; Burkhart CA; Regl DL; Norris MD; Haber M; Horwitz SB, 1997, 'Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes', Journal of Clinical Investigation, vol. 100, pp. 1282 - 1293, http://dx.doi.org/10.1172/JCI119642

Norris MD; Bordow SB; Haber PS; Marshall GM; Kavallaris M; Madafiglio J; Cohn SL; Salwen H; Schmidt ML; Hipfner DR, 1997, 'Evidence that the MYCN oncogene regulates MRP gene expression in neuroblastoma', European Journal of Cancer, vol. 33, pp. 1911 - 1916, http://dx.doi.org/10.1016/S0959-8049(97)00284-0

Haber M; Bordow SB; Haber PS; Marshall GM; Stewart BW; Norris MD, 1997, 'The prognostic value of MDR1 gene expression in primary untreated neuroblastoma', European Journal of Cancer, vol. 33, pp. 2031 - 2036, http://dx.doi.org/10.1016/S0959-8049(97)00229-3

Norris MD; Kwan E; Zhu L; Marshall GM; Haber M, 1996, 'Sensitive non radioactive PCR detection of minimal residual leukaemia using TCR(gamma) gene rearrangements', BRITISH JOURNAL OF HAEMATOLOGY, vol. 93, pp. 225 - 225, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1996UP11400225&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Cheung B; Hocker JE; Smith SA; Reichert U; Norris MD; Haber M; Stewart BW; Marshall GM, 1996, 'Retinoic acid receptors β and γ distinguish retinoid signals for growth inhibition and neuritogenesis in human neuroblastoma cells', Biochemical and Biophysical Research Communications, vol. 229, pp. 349 - 354, http://dx.doi.org/10.1006/bbrc.1996.1804

Norris MD; De Graaf D; Haber M; Kavallaris M; Madafiglio J; Gilbert J; Kwan E; Stewart BW; Mechetner EB; Gudkov AV, 1996, 'Involvement of MDR1 P-glycoprotein in multifactorial resistance to methotrexate', International Journal of Cancer, vol. 65, pp. 613 - 619, http://dx.doi.org/10.1002/(SICI)1097-0215(19960301)65:5<613::AID-IJC10>3.0.CO;2-8

Norris MD; Bordow SB; Marshall GM; Haber PS; Cohn SL; Haber M, 1996, 'Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma', New England Journal of Medicine, vol. 334, pp. 231 - 238, http://dx.doi.org/10.1056/NEJM199601253340405

Norris MD; Bordow SB; Marshall GM; Heber PS; Cohn S; Haber M, 1996, 'Association between high levels of expression of the multidrug resistance-associated protein (MRP) gene and poor outcome in primary human neuroblastoma', New England Journal of Medicine, pp. 231 - 238

Marshall GM; Kwan E; Haber M; Brisco MJ; Sykes PJ; Morley AA; Toogood I; Waters K; Tauro G; Ekert H, 1995, 'Characterization of clonal immunoglobulin heavy chain and T cell receptor γ gene rearrangements during progression of childhood acute lymphoblastic leukemia', Leukemia, vol. 9, pp. 1847 - 1850

Haber M; Burkhart CA; Regl DL; Madafiglio J; Norris MD; Horwitz SB, 1995, 'Altered expression of Mβ2, the class II β-tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance', Journal of Biological Chemistry, vol. 270, pp. 31269 - 31275, http://dx.doi.org/10.1074/jbc.270.52.31269

Norris MD; Gilbert J; Madafiglio J; Haber M, 1995, 'Analysis of a novel cDNA encoding a C219-reactive peptide isolated from methotrexate-selected multidrug-resistant human leukemic cells', Gene, vol. 156, pp. 313 - 314, http://dx.doi.org/10.1016/0378-1119(94)00541-Y

Marshall GM; Cheung B; Stacey KP; Camacho ML; Simpson AM; Kwan E; Smith S; Haber M; Norris MD, 1995, 'Increased retinoic acid receptor gamma expression suppresses the malignant phenotype and alters the differentiation potential of human neuroblastoma cells', Oncogene, vol. 11, pp. 485 - 491

Norris MD; Kwan E; Haber M; Marshall GM, 1995, 'Detection of evolving immunoglobulin heavy-chain gene rearrangements in acute lymphoblastic leukemia: A PCR-based assay employing overlapping DJHprimers', Leukemia, vol. 9, pp. 1779 - 1782

Haber M; Norris MD; Kavallaris M; Camacho M; Madafiglio J; Baker CJ; White L; Stewart BW, 1995, 'An assay for the determination of reduced methotrexate accumulation in cells displaying limited viability in vitro', Cancer Letters, vol. 97, pp. 49 - 55, http://dx.doi.org/10.1016/0304-3835(95)03950-2

Marshall GM; Cheung B; Stacey KP; Norris MD; Haber M, 1994, 'Regulation of retinoic acid receptor alpha expression in human neuroblastoma cell lines and tumor tissue', Anticancer Research, vol. 14, pp. 437 - 441

Haber M; Madafiglio J; Bordow SB; Gilbert J; Cheung B; Marshall GM; Norris MD, 1994, 'Expression of retinoic acid-responsive genes in primary neuroblastomas.', Progress in clinical and biological research, vol. 385, pp. 245 - 251

Marshall GM; Cheung B; Stacey KP; Norris MD; Haber M, 1994, 'Regulation of retinoic acid receptor alpha expression in human neuroblastoma cell lines and tumor tissue.', Anticancer Res, vol. 14, pp. 437 - 441, https://www.ncbi.nlm.nih.gov/pubmed/8017844

Norris MD; Haber M; Gilbert J; Kavallaris M; Marshall GM; Stewart BW, 1994, 'N-myc gene amplification in neuroblastoma determined by the polymerase chain reaction.', Progress in clinical and biological research, vol. 385, pp. 27 - 33

Bordow SB; Haber M; Madaflglio J; Cheung B; Marshall GM; Norris MD, 1994, 'Expression of the Multidrug Resistance-associated Protein (MRP) Gene Correlates with Amplification and Overexpression of the N-myc Oncogene in Childhood Neuroblastoma', Cancer Research, vol. 54, pp. 5036 - 5040

Haber M; Madafiglio J; Norris MD, 1993, 'Methotrexate cytotoxicity determination using the MTT assay following enzymatic depletion of thymidine and hypoxanthine', Journal of Cancer Research and Clinical Oncology, vol. 119, pp. 315 - 317, http://dx.doi.org/10.1007/BF01208836

Selig RA; Madafiglio J; Haber M; Norris MD; White L; Stewart BW, 1993, 'Ferritin production and desferrioxamine cytotoxicity in human neuroblastoma cell lines', Anticancer Research, vol. 13, pp. 721 - 725

Gilbert J; Norris MD; Haber M; Kavallaris M; Marshall GM; Stewart BW, 1993, 'Determination of n-myc gene amplification in neuroblastoma by differential polymerase chain reaction', Molecular and Cellular Probes, vol. 7, pp. 227 - 234, http://dx.doi.org/10.1006/mcpr.1993.1033

Kavallaris M; Madafiglio J; Norris MD; Haber M, 1993, 'Resistance to Tetracycline, a Hydrophilic Antibiotic, Is Mediated by P-Glycoprotein in Human Multidrug-Resistant Cells', Biochemical and Biophysical Research Communications, vol. 190, pp. 79 - 85, http://dx.doi.org/10.1006/bbrc.1993.1013

Kavallaris M; Haber M; Norris MD; Matherly LH; Stewart BW, 1991, 'Characterization of Mechanisms Mediating Drug Resistance in Human Leukemic Cells Selected with High Concentration Methotrexate', Pteridines, vol. 3, pp. 119 - 121, http://dx.doi.org/10.1515/pteridines.1991.3.12.119

Norris MD; Haber M; Kavallaris M; Brian MJ; Lutze LH; White L; Stewart BW, 1991, 'Reduced drug accumulation as the mechanism of extreme clinical resistance to methotrexate in the human T‐cell leukemia xenograft, LALW‐2', Cancer, vol. 68, pp. 981 - 987, http://dx.doi.org/10.1002/1097-0142(19910901)68:5<981::AID-CNCR2820680512>3.0.CO;2-W

Kavallaris M; Haber M; Norris MD; Pittman SM; Reed C; Stewart BW, 1990, 'Phenotypic and cytogenetic analysis of atypical multidrug resistance in human leukaemic cells selected with methotrexate at high concentration', Cancer Letters, vol. 51, pp. 193 - 201, http://dx.doi.org/10.1016/0304-3835(90)90102-4

Norris MD; Haber M; King M; Davey RA, 1989, 'Atypical multidrug resistance in CCRF-CEM cells selected for high level methotrexate resistance: Reactivity to monoclonal antibody C219 in the absence of P-glycoprotein expression', Biochemical and Biophysical Research Communications, vol. 165, pp. 1435 - 1441, http://dx.doi.org/10.1016/0006-291X(89)92764-2

White L; Haber M; Brian MJ; Norris MD; Trickett A; Sosula L; Tiley C; Stewart BW, 1989, 'Therapy‐induced drug resistance in a human leukemia line (LALW‐2)', Cancer, vol. 63, pp. 2103 - 2110, http://dx.doi.org/10.1002/1097-0142(19890601)63:11<2103::AID-CNCR2820631106>3.0.CO;2-N

Haber M; Reed C; Kavallaris M; Norris MD; Stewart BW, 1989, 'Resistance to drugs associated with the multidrug resistance phenotype following selection with high-concentration methotrexate', Journal of the National Cancer Institute, vol. 81, pp. 1250 - 1254, http://dx.doi.org/10.1093/jnci/81.16.1250

Haber M; Norris MD; Kavallaris M; White L; Stewart BW; Bell DR; Davey RA, 1989, 'Atypical Multidrug Resistance in a Therapy-induced Drug-resistant Human Leukemia Cell Line (LALW-2): Resistance to Vinca Alkaloids Independent of P-Glycoprotein', Cancer Research, vol. 49, pp. 5281 - 5287

HABER M; KAVALLARIS M; STEWART BW, 1986, '2-STAGE INCORPORATION OF THYMIDINE TRIPHOSPHATE INTO MAMMALIAN DNA AS INDICATED BY CHROMATOGRAPHY ON BENZOYLATED DEAE-CELLULOSE', JOURNAL OF CHROMATOGRAPHY, vol. 382, pp. 127 - 134, http://dx.doi.org/10.1016/S0378-4347(00)83511-2

Stewart BW; Haber M; Ward EJ, 1986, 'Digestion of repair sites in rat liver DNA by endogenous nucleases.', Biochemistry International, vol. 13, pp. 903 - 913

Haber M; Kavallaris M; Stewart BW, 1986, 'Two-stage incorporation of thymidine triphosphate into mammalian DNA as indicated by chromatography on benzoylated DEAE-cellulose', Journal of Chromatography - Biomedical Applications, vol. Vol. 382, pp. 127 - 134

Haber M; Kavallaris M; Stewart BW, 1986, 'Two-stage incorporation of thymidine triphosphate into mammalian DNA as indicated by chromatography on benzoylated DEAE-cellulose', Journal of Chromatography B: Biomedical Sciences and Applications, vol. 382, pp. 135 - 145, http://dx.doi.org/10.1016/S0378-4347(00)83512-4

Haber M; Stewart BW, 1985, 'Oncogenes. A possible role for cancer genes in human malignant disease', Medical Journal of Australia, vol. 142, pp. 402 - 409

Stewart BW; Hristofordis C; Haber M; Ward EJ, 1985, 'Enhancement of nitrosamine-induced structural damage in rat liver DNA by cell division', Proceedings of the American Association for Cancer Research, vol. VOL. 26

Stewart BW; Hristoforidis C; Haber M, 1985, 'Dose-dependent persistence of alkylation-induced single stranded regions in rat liver DNA in vivo', Cancer Letters, vol. 28, pp. 27 - 33, http://dx.doi.org/10.1016/0304-3835(85)90088-6

Haber M; Stewart BW, 1985, 'Patterns of structural change in DNA during tissue necrosis indicated by benzoylated DEAE-cellulose chromatography', Chemico-Biological Interactions, vol. 53, pp. 247 - 255, http://dx.doi.org/10.1016/S0009-2797(85)80102-2

STEWART BW; HRISTOFORDIS C; HABER M; WARD EJ, 1985, 'ENHANCEMENT OF NITROSAMINE-INDUCED STRUCTURAL DAMAGE IN RAT-LIVER DNA BY CELL-DIVISION', PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 26, pp. 97 - 97, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1985AGD9400383&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Ward EJ; Haber M; Norris MD; Stewart BW, 1985, 'Single-Strand-Specific Degradation of DNA during Isolation of Rat Liver Nuclei†', Biochemistry, vol. 24, pp. 5803 - 5809, http://dx.doi.org/10.1021/bi00342a018

STEWART BW; HABER M; HRISTOFORIDIS C, 1984, 'FACTORS AFFECTING THE PERSISTENCE OF ALKYLATION-INDUCED STRUCTURAL DAMAGE IN DNA INVIVO', PROCEEDINGS OF THE AUSTRALIAN BIOCHEMICAL SOCIETY, vol. 16, pp. S18 - S18, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1984ANC4600033&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

WARD EJ; HABER M; STEWART BW, 1984, 'DIFFERENTIAL REPAIR OF ALKYLATION DAMAGE IN RAT-LIVER CHROMATIN', MEDICAL AND PEDIATRIC ONCOLOGY, vol. 12, pp. 278 - 279, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1984TC60000027&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Haber M; Huang PHT; Stewart BW, 1984, 'Limitations on the stability of benzoylated DEAE-cellulose', Analytical Biochemistry, vol. 139, pp. 363 - 366, http://dx.doi.org/10.1016/0003-2697(84)90018-6

HABER M; STEWART BW, 1983, 'REPLICATIVE INTERMEDIATES IN MAMMALIAN DNA', PROCEEDINGS OF THE AUSTRALIAN BIOCHEMICAL SOCIETY, vol. 15, pp. 69 - 69, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1983RC51300166&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

HABER M; STEWART BW, 1983, 'STRUCTURAL INTERMEDIATES GENERATED DURING REPLICATION OF MAMMALIAN DNA', MEDICAL AND PEDIATRIC ONCOLOGY, vol. 11, pp. 198 - 199, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1983QX04200045&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

HABER M; STEWART BW, 1981, 'ANALYSIS OF CHEMICALLY-INDUCED STRUCTURAL-CHANGE IN DNA BY BENZOYLATED-DEAE-CELLULOSE CHROMATOGRAPHY', PROCEEDINGS OF THE AUSTRALIAN BIOCHEMICAL SOCIETY, vol. 14, pp. 90 - 90, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1981LR25400218&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Haber M; Stewart BW, 1981, 'Sizing of DNA fragments by preparative, benzoylated DEAE-cellulose chromatography', FEBS Letters, vol. 133, pp. 72 - 74, http://dx.doi.org/10.1016/0014-5793(81)80473-5

Tsoli M; Luk P; Dilda P; Hogg P; Haber M; Ziegler D, 2013, 'TARGETING MITOCHONDRIA AND METABOLISM AS A NOVEL THERAPEUTIC APPROACH IN THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, Fort Lauderdale, FL, pp. 21 - 21, presented at 2nd Annual Pediatric Neuro-Oncology Basic and Translational Research Conference, Fort Lauderdale, FL, 16 - 17 May 2013, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000318570500078&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Norris MD; Smith J; Kwek A; Flemming C; Cohn SL; London WB; Buxton A; Marshall GM; Haber M, 2007, 'Expression of the multidrug transporter genes ABCC1/MRP1, ABCC3/MRP3, and ABCC4/MRP4 are powerful predictors of clinical outcome in childhood neuroblastoma', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000455043702481&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Burkhart CA; Watt F; Pajic M; Murray J; Xue C; Flemming C; Smith J; Marshall GM; Haber M; Norris MD, 2006, 'Selective Sensitization of murine tumors to chemotherapy by a novel class of non-toxic small molecule inhibitors of MRP1', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000454606201252&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Laughton SJ; Ashton LJ; Kwan E; Norris MD; Haber M; Marshall GM, 2003, 'Early markers of the therapeutic index in children with acute lymphoblastic leukaemia predict outcome.', in BLOOD, AMER SOC HEMATOLOGY, SAN DIEGO, CALIFORNIA, pp. 879A - 879A, presented at 45th Annual Meeting of the American-Society-of-Hematology, SAN DIEGO, CALIFORNIA, 06 - 09 December 2003, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000186536703271&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Verrills N; Flemming C; Liu M; Ivery M; Norris MD; Haber M; Kavallaris M, 2002, 'Acquired beta-tubulin mutations affecting microtubule stability and drug binding', in MOLECULAR BIOLOGY OF THE CELL, AMER SOC CELL BIOLOGY, SAN FRANCISCO, CALIFORNIA, pp. 463A - 463A, presented at 42nd Annual Meeting of the American-Society-for-Cell-Biology, SAN FRANCISCO, CALIFORNIA, 14 - 18 December 2002, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000179569102604&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Lock RB; Liem N; Tajbakhsh M; Milross CG; Xue CY; Haber M; Norris MD; Marshall GM; Rice AM, 2001, 'Novel biological characteristics and disparate vincristine responses of primary childhood acute lymphoblastic leukemia cells engrafted into non-obese diabetic/severe combined immunodeficient mice.', in BLOOD, AMER SOC HEMATOLOGY, pp. 309A - 310A, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000172134101312&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a